TY - JOUR
T1 - Development of the influence, motivation, and patient activation in diabetes (IMPACT-D™) measure
AU - Arvanitis, Marina
AU - Bailey, Stacy Cooper
AU - Wismer, Guisselle
AU - Griffith, James W.
AU - Freeman, Emily
AU - Sims, Tracy J.
AU - Paczkowski, Rosirene
AU - Klopchin, Megan
AU - Chung, Arlene E.
AU - Carpenter, Delesha M.
AU - Wolf, Michael S.
N1 - Funding Information:
This study was funded by Eli Lilly and Company. 6
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/1
Y1 - 2020/1
N2 - Aims: We sought to create a new research and clinical instrument –the Influence and Motivation for Patient ACTivation in Diabetes care (IMPACT-D™) - to measure the degree to which patients with type 2 diabetes (T2DM) value health and believe they can influence it. Methods: Candidate items were generated via a literature review, expert opinion, and qualitative interviews and focus groups with T2DM patients in Chicago, IL and Chapel Hill, NC. Psychometric testing guided by item response theory was conducted among an online panel of 500 English-speaking adults with T2DM. Differential item functioning analyses evaluated item performance across key participant characteristics. To determine construct validity, IMPACT-D™ scores were compared to other general measures of personality and patient activation. A second study among 300 patients recruited from two internal medicine clinics further assessed associations between the IMPACT-D™ and health outcomes. Cognitive interviews confirmed patient understanding of IMPACT-D™ items and instructions. Results: Exploratory factor analyses revealed a single-factor solution that included 6 items. The IMPACT-D™ demonstrated adequate reliability (α = 0.72) and moderate construct validity with patient activation (r = 0.51, p < 0.001) and personality-conscientiousness subscales (r = 0.29, p < 0.001). Higher scores on the IMPACT-D™ were associated with better physical health (r = 0.17, p = 0.003) and lower severity of depressive (r = −0.35, p < 0.001) and anxiety (r = −0.28, p < 0.001) symptoms. There were no significant differences by blood pressure (r = −0.0021, p = 0.9) or haemoglobin A1c (r = −0.069p = 0.2). Conclusions: The IMPACT-D holds potential for use in both clinical care and research applications. Future studies should evaluate how to best operationalize its use for both settings.
AB - Aims: We sought to create a new research and clinical instrument –the Influence and Motivation for Patient ACTivation in Diabetes care (IMPACT-D™) - to measure the degree to which patients with type 2 diabetes (T2DM) value health and believe they can influence it. Methods: Candidate items were generated via a literature review, expert opinion, and qualitative interviews and focus groups with T2DM patients in Chicago, IL and Chapel Hill, NC. Psychometric testing guided by item response theory was conducted among an online panel of 500 English-speaking adults with T2DM. Differential item functioning analyses evaluated item performance across key participant characteristics. To determine construct validity, IMPACT-D™ scores were compared to other general measures of personality and patient activation. A second study among 300 patients recruited from two internal medicine clinics further assessed associations between the IMPACT-D™ and health outcomes. Cognitive interviews confirmed patient understanding of IMPACT-D™ items and instructions. Results: Exploratory factor analyses revealed a single-factor solution that included 6 items. The IMPACT-D™ demonstrated adequate reliability (α = 0.72) and moderate construct validity with patient activation (r = 0.51, p < 0.001) and personality-conscientiousness subscales (r = 0.29, p < 0.001). Higher scores on the IMPACT-D™ were associated with better physical health (r = 0.17, p = 0.003) and lower severity of depressive (r = −0.35, p < 0.001) and anxiety (r = −0.28, p < 0.001) symptoms. There were no significant differences by blood pressure (r = −0.0021, p = 0.9) or haemoglobin A1c (r = −0.069p = 0.2). Conclusions: The IMPACT-D holds potential for use in both clinical care and research applications. Future studies should evaluate how to best operationalize its use for both settings.
UR - http://www.scopus.com/inward/record.url?scp=85077110336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077110336&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2019.107965
DO - 10.1016/j.diabres.2019.107965
M3 - Article
C2 - 31805349
AN - SCOPUS:85077110336
SN - 0168-8227
VL - 159
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 107965
ER -